查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1854685

胃腸道疾病藥物市場按適應症、藥物類別、給藥途徑、通路、劑型和最終用戶分類－2025-2032年全球預測

Gastrointestinal Diseases Therapeutics Market by Indication, Drug Class, Route Of Administration, Distribution Channel, Dosage Form, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，胃腸道疾病藥物市場將成長至 577.1 億美元，複合年成長率為 4.10%。

關鍵市場統計數據
基準年 2024 418.2億美元
預計年份：2025年 435.2億美元
預測年份 2032 577.1億美元
複合年成長率 (%) 4.10%

這篇精闢的導言概述了正在重新定義胃腸道疾病治療策略的臨床、商業和營運動態。

胃腸道治療領域正處於臨床複雜性、技術創新以及不斷變化的支付方和監管機構期望的交匯點。生物製藥的研發、對微生物組的日益關注以及精準診斷的復興，共同再形成了從酸相關疾病到發炎性腸道疾病等多種疾病的研發重點。同時，醫療系統要求提供更清晰的真實世界價值證據，這正在改變臨床項目的規劃方式和商業化策略的優先順序。

在此背景下，相關人員必須兼顧短期營運挑戰與長期治療機會。供應鏈韌性、監管靈活性和差異化臨床終點對計畫的可行性日益重要。此外，以患者為中心的護理模式與數位醫療的融合正在重新定義慢性胃腸疾病的依從性、監測和療效評估。因此，決策者需要一種綜合觀點，將臨床創新與商業性可行性以及在醫院、診所和家庭醫療保健機構的實際應用聯繫起來。

本執行摘要提煉了影響關鍵適應症和產品類別療法開發、上市和市場准入的核心動態。它重點闡述了需求結構性變化、監管和政策影響，以及產業領導者可採取的行動要點。透過將臨床趨勢與營運和商業現實相結合，本概要旨在為企業高管和投資者提供一個聚焦的觀點，以幫助他們確定投資重點、建立夥伴關係關係並加速提升患者獲益。

全面、前瞻性地闡述了推動胃腸道藥物研發和遞送領域根本性變革的科學、監管和商業性因素。

胃腸道治療領域正經歷一場變革，其驅動力包括科學突破、監管改革和醫療模式的轉變。首先，生物製藥和標靶免疫調節劑的成熟正推動研發工作轉向精準的作用機制研究，尤其是在發炎性腸道疾病領域，抗整合素抑制劑和白細胞介素抑制劑已徹底改變了治療流程。同時，人們對腸道微生物組的重新關注也促進了對微生物組療法和非傳統治療方法的投資，並有望開發出超越傳統小分子化合物和質子幫浦抑制劑的新型治療方法。

同時，監管機構正著重強調適應性路徑和真實世界證據，並以此指導試驗設計和上市後承諾。這種監管轉變有利於那些在研發早期就整合可操作終點、縱向病患監測和衛生經濟學分析的計畫。此外，醫院專科藥房在複雜生技藥品的供應方面繼續發揮至關重要的作用。

最後，隨著支付方日益重視可證明的價值和成本效益，商業性格局正在改變。製造商正透過創新定價和循證策略來應對，包括基於結果的合約和風險分擔安排。總而言之，這些變化需要一項整合策略，才能將科學進步轉化為永續的患者可及性和商業性成功。

對近期關稅調整如何重塑胃腸道治療藥物供應鏈、生產決策和商業談判進行策略評估

美國將於2025年實施新的關稅，將對全球胃腸道治療藥物的供應鏈、籌資策略和成本結構產生連鎖反應。關稅調整可能會影響活性藥物原料藥的成本，尤其是那些從國際供應商採購的活性藥物成分，從而加大依賴跨境生產或大宗原料進口的製造商的價格壓力。因此，各公司需要重新評估籌資策略和合約條款，以在確保產品品質和供應連續性的同時，保護淨利率。

除了直接的成本影響外，關稅還可能加速製造業地域佈局和垂直整合的策略轉變。企業可能會透過將關鍵中間體的生產轉移到近岸地區、擴大國內契約製造或與供應商談判簽訂長期合約來降低價格波動。這些應對措施通常需要資本投資和延長前置作業時間，這可能會影響臨床供應和商業部署的時間表。此外，關稅相關的成本增加可能會影響與支付方和醫院系統的價格談判，促使製造商積極投資於價值驗證和真實世界證據，以證明其定價決策的合理性。

關稅政策帶來的不確定性也將影響投資者情緒和併購活動。有些投資者在進行重大交易前，會尋求更清晰的供應鏈風險緩解措施，而有些投資者則會將關稅視為促進整合和策略夥伴關係的催化劑，以確保在地化生產。最終，採取多管齊下應對措施（包括供應商多元化、合約保護以及與支付方和購買方進行透明溝通）的公司，將更有能力應對累積影響，同時保障患者獲得必要的胃腸道藥物。

深入的細分分析，重點關注臨床、製劑和管道方面的差異化因素，這些因素驅動著各個治療類別的產品採納路徑和商業化重點。

細分市場層面的洞察揭示了不同適應症、藥物類別、給藥途徑、分銷管道、劑型和終端用戶之間存在的細微機會和限制因素。同時，感染性胃腸炎涵蓋細菌性、感染疾病和病毒性胃腸炎，這些疾病的急性期治療和抗菌藥物管理方案各不相同。發炎性腸道疾病分為克隆氏症和潰瘍性大腸炎，二者的外科和生物治療方案也不同。大腸激躁症分為便秘型、腹瀉型和混合型，需要針對不同症狀採取相應的治療策略。

按藥物類別分類，氨基水楊酸鹽、抗生素、止瀉藥、解痙藥、H2受體拮抗劑、瀉藥和質子幫浦阻斷劑等傳統藥物類別繼續滿足核心治療需求，而生物製藥及其亞型，例如抗整合素藥物、抗腫瘤壞死因子藥物和白細胞介素抑制劑，則在中差異性發炎性疾病中展現出重度發炎的價值。在抗生素中，Ciprofloxacin、甲硝唑和Rifaximin等藥物在治療不同的感染病因方面各有其特異性作用，凸顯了藥物管理和抗藥性監測的重要性。給藥途徑，無論是口服、注射或局部，都會影響病人的依從性、治療環境要求、製劑創新重點。

分銷管道，包括醫院藥房、線上藥房和零售藥房，各自不同的商業性和監管動態會影響報銷、病患用藥和依從性。劑型，包括注射液、口服粉劑、口服混懸液和膠囊劑，決定了生產的複雜性、低溫運輸要求以及給藥方式創新的機會。最後，終端使用者細分，包括診所、家庭醫療保健和醫院，決定了新治療方法的推廣路徑和培訓需求。綜上所述，這些細分洞察表明，成功的產品策略必須全面協調適應症特定的臨床需求、差異化的分子類別、實際可行的給藥途徑和用途，以及針對特定管道和終端用戶的商業化計劃。

區域比較視角著重分析監管、支付方和基礎設施的差異，這些差異影響全球市場准入、市場接受度和供應策略。

區域動態，反映了法律規範、醫療服務體系和患者群體方面的差異，對制定研發重點和市場推廣策略至關重要。美洲地區擁有強大的臨床研究基礎設施、完善的支付體系和先進的專科醫療網路，為創新生技藥品和複雜治療方法的引入提供了支持，但同時也面臨著嚴格的證據要求和價格壓力。因此，製造商必須優先考慮可靠的臨床終點和衛生經濟學證據，以確保在這些市場中獲得處方地位和報銷。

在歐洲、中東和非洲，監管環境和報銷機制的多樣性既帶來了機遇，也帶來了挑戰。西方市場往往需要全面的療效比較數據和基於價值的論證，而該地區的新興市場則可能更注重可負擔性和供應鏈的可靠性。同時，中東和非洲在醫療基礎設施不斷完善和慢性病負擔日益加重的推動下，蘊藏著巨大的成長潛力，但每個地區都需要製定量身定做的准入策略，並充分考慮當地的採購流程。因此，採取協調一致的區域性方法，平衡集中式的證據產生和局部化的商業化策略至關重要。

亞太地區醫療保健投資的快速成長、生技藥品生產基地的不斷擴大以及法規結構的持續演進是該地區的關鍵主題。該地區的多個市場正在加強本地臨床試驗能力，並加速新型療法的核准。如果與監管策略協調一致，這些措施可以縮短產品上市時間。然而，價格敏感度和多樣化的報銷機制要求採用彈性價格設定和合作模式。總而言之，區域策略必須考慮不同的監管預期、支付方行為以及醫療服務基礎設施，才能將科學進步轉化為病患可近的醫療保健服務。

整合企業策略和生態系統夥伴關係，揭示創新、製造和數位融合如何重塑該產業的競爭優勢。

胃腸道治療領域的公司層面動態反映了一系列策略態勢，涵蓋了從專注於創新的生物技術公司到大型製造商和專業合約服務提供者。創新公司致力於開發下一代生技藥品、標靶小分子藥物和微生物療法，通常利用精準醫療方法和生物標記主導的臨床試驗來識別有效人群。這些公司正與臨床研究網路和學術中心建立策略聯盟，以加速概念驗證試驗並檢驗差異化的臨床終點。

同時，現有製藥公司和學名藥企業正透過生命週期管理、生物相似藥開發和製劑改進來最佳化其產品組合，從而提高患者的用藥便利性和依從性。受託製造廠商）和專業CDMO正在拓展其能力，以支持注射用生技藥品和複雜口服製劑的生產，這影響著申辦方的產品上市速度和成本結構。在整個生態系統中，策略合作、授權協議和有針對性的收購仍然是補充內部能力和填補產品線缺口的常用機制。

最後，新興企業和數位醫療領域的參與企業正在將遠端監測、患者報告結果和依從性技術整合到其產品中，以增強真實世界證據的收集和價值展示。治療藥物研發企業和正在開發數位解決方案的合作夥伴正在加強上市後監測和與支付方的談判。總而言之，那些能夠將科學差異化與卓越營運、符合支付方需求的證據策略以及敏捷的商業化模式相結合的公司，將在競爭激烈的市場環境中佔據優勢。

以營運為導向的建議，整合供應鏈韌性、證據完整性和交付創新，以增強胃腸道治療的臨床和商業性成果。

行業領導者應採取一系列切實可行的措施，將科學進步轉化為永續的商業性成果和更佳的患者照護。首先，應優先考慮供應鏈韌性，透過多元化關鍵活性藥物原料藥的供應商，並協商靈活的合約來降低關稅和地緣政治風險。投資於雙重採購策略並加強與製造外包的關係，將有助於降低脆弱性，並確保臨床和商業供應的連續性。

第二，透過早期參與終點指標、衛生經濟學和真實世界證據的收集，使臨床開發與支付方的期望保持一致，從而促進價值對話並支持處方談判。第三，透過最佳化劑型和給藥途徑，提高病患依從性並支持居家照護，加速給藥創新。

第四，我們將尋求策略聯盟，整合我們在生技藥品開發、微生物組科學和數位健康領域的優勢，建構差異化的證據包和患者支持解決方案。第五，我們將採用靈活的商業化模式，根據當地通路動態調整分銷策略，在與醫院藥局的合作以及零售藥局和線上藥局的通路拓展之間取得平衡。最後，我們將加強在監管策略、市場進入和商業分析方面的組織能力，以便快速應對政策變化和支付方需求的轉變。這些措施將鞏固我們的市場地位，並改善患者的治療效果。

我們採用透明的多來源調查方法，結合文獻綜合、專家參與和情境分析，以檢驗我們的策略見解和建議。

本分析的調查方法整合了多方面的證據來源，並採用迭代檢驗步驟以確保其穩健性和有效性。首先，透過全面的二次檢索，整合了同儕審查的臨床文獻、監管指南、專利申請和治療指南，建立了關於治療機制、臨床終點和標準治療實踐的基準。這項基礎研究確定了關鍵的知識空白，並為後續的初步研究指明了方向。

主要研究包括對臨床專家、支付方代表、生產專家和商業領袖進行結構化訪談，以了解當前的實踐模式、定價和報銷觀點以及營運限制。訪談結果與監管文件和已發表的臨床試驗結果進行交叉比對，以驗證論點並消除差異。此外，也運用情境分析來評估供應鏈突發事件和政策影響，並考慮應對關稅變化和生產中斷的合理措施。

品質保證措施包括交叉檢驗資訊資訊來源、專家同行評審以及對假設和限制的透明記錄。倫理考量包括保護受訪者的隱私並遵守資料隱私標準。儘管我們盡一切努力確保全面覆蓋，但使用者仍應結合不斷變化的臨床證據和政策發展來解讀研究結果。因此，我們的調查方法結合了嚴謹的文獻綜述、相關人員參與和分析建模，旨在為決策者提供可操作的資訊。

簡潔扼要的結論總結了策略要務，強調需要採取綜合性的、兼顧本地實際情況的方法，將創新轉化為對病人的影響。

總之，胃腸道治療格局正受到多種因素的共同影響而重塑：生物製藥和微生物組研究領域的科學創新、強調真實世界證據的監管環境、支付方對價值的不斷變化以及供應鏈和政策變化帶來的營運壓力。應對這些變化需要整合策略。那些積極主動地將證據產生與支付方需求結合、實現供應鏈多元化並投資於給藥創新技術的機構，將在改善患者療效的同時，獲得競爭優勢。

此外，不同地區的監管和報銷環境存在細微差異，因此一刀切的方法並不適用。量身定做的策略、靈活的製造地以及協作夥伴關係關係對於實現臨床療效和商業性永續性至關重要。這些舉措將共同建構一個更具韌性、以患者為中心的醫療生態系統，使其能夠適應政策變化和不斷發展的臨床實踐。

因此，我們鼓勵相關人員將這些戰略要務轉化為具體舉措，優先考慮那些能夠展現臨床差異化、營運穩健性以及對支付方和醫療保健提供者俱有明顯價值的計劃，這將加速將科學突破轉化為胃腸道疾病患者可及且有效的治療方法。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 腸道菌叢治療性介入在大腸激躁症治療的應用日益廣泛
  • 針對發炎性腸道疾病黏膜癒合策略的生技藥品和生物相似藥研發管線的成長
  • 擴大口服小分子激酶抑制劑在克隆氏症和潰瘍性大腸炎治療的應用
  • 用於早期檢測胃腸道癌症的非侵入性診斷生物標記的研究進展
  • 在大腸直腸癌治療方案選擇中，對採用基因譜分析的個人化醫療方法的需求日益成長。
  • 居家遠端醫療監測和數位藥物依從性工具在慢性胃腸道疾病的應用
  • 加強製藥公司和生物技術公司之間的策略聯盟，以實現基於微生物組的治療方法的商業化
  • 增加對下一代胜肽療法的投資，以解決功能性消化不良和胃輕癱的症狀

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：以適應症分類的胃腸道疾病藥物市場

  • 與酸相關的疾病
    • 消化不良
    • 胃食道逆流症
    • 消化性潰瘍
  • 傳染性腸胃炎
    • 細菌性腸胃炎
    • 寄生蟲感染疾病
    • 病毒性腸胃炎
  • 發炎性腸道疾病
    • 克隆氏症
    • 潰瘍性大腸炎
  • 大腸激躁症
    • 便秘是主要
    • 腹瀉是主要症狀。
    • 混合型

9. 按藥物類別分類的胃腸道疾病藥物市場

  • 氨基水楊酸鹽
  • 抗生素
    • Ciprofloxacin
    • 甲硝唑
    • Rifaximin
  • 止瀉
  • 解痙藥
  • 生物製藥
    • 抗整合素藥物
    • 抗腫瘤壞死因子藥物
    • 白細胞介素抑制劑
  • H2受體拮抗劑
  • 瀉藥
  • 質子幫浦抑制劑

第10章 依給藥途徑分類的胃腸道疾病藥物市場

  • 口服
  • 腸外
  • 話題

第11章 胃腸道疾病藥物市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 胃腸道疾病藥物市場（依劑型分類）

  • 注射液
  • 口服粉劑
  • 口服懸浮液
  • 片劑 膠囊

第13章：依最終使用者分類的胃腸道疾病藥物市場

  • 診所
  • 家庭醫療保健
  • 醫院

第14章：各地區胃腸道疾病藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 胃腸道疾病藥物市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國胃腸道疾病藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • AbbVie Inc.
    • Johnson & Johnson
    • Takeda Pharmaceutical Company Limited
    • Pfizer Inc.
    • Novartis AG
    • Ferring BV
    • Gilead Sciences, Inc.
    • Bausch Health Companies Inc.
    • AstraZeneca PLC
    • UCB SA
Product Code: MRR-957C47F91DC1

The Gastrointestinal Diseases Therapeutics Market is projected to grow by USD 57.71 billion at a CAGR of 4.10% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 41.82 billion
Estimated Year [2025] USD 43.52 billion
Forecast Year [2032] USD 57.71 billion
CAGR (%) 4.10%

An incisive introduction outlining evolving clinical, commercial, and operational dynamics that are redefining therapeutic strategies across gastrointestinal disease care

The gastrointestinal therapeutics landscape sits at the intersection of clinical complexity, technological innovation, and evolving payer and regulatory expectations. Advances in biologics, growing attention to the microbiome, and a resurgence in precision diagnostics have collectively reshaped development priorities for conditions ranging from acid-related disorders to inflammatory bowel disease. At the same time, healthcare systems are demanding clearer evidence of real-world value, which is changing how clinical programs are designed and how commercialization strategies are prioritized.

Against this backdrop, stakeholders must reconcile short-term operational challenges with long-term therapeutic opportunity. Supply chain resiliency, regulatory agility, and differentiated clinical endpoints are increasingly central to program viability. Moreover, patient-centric care models and digital health integrations are redefining adherence, monitoring, and outcome measurement for chronic gastrointestinal conditions. Consequently, decision-makers need an integrated view that links clinical innovation with commercial viability and practical deployment in hospitals, clinics, and home healthcare environments.

This executive summary distills core dynamics shaping therapeutic development, delivery, and market access across key indications and product classes. It highlights structural shifts in demand, regulatory and policy influences, and actionable imperatives for industry leaders. By synthesizing clinical trends with operational and commercial realities, the narrative aims to equip executives and investors with a focused perspective for prioritizing investment, structuring partnerships, and accelerating patient impact.

A forward-looking synthesis of scientific, regulatory, and commercial forces that are driving fundamental transformation across gastrointestinal therapeutics development and delivery

The landscape of gastrointestinal therapeutics is undergoing transformative shifts driven by scientific breakthroughs, regulatory evolution, and changing care models. First, the maturation of biologic platforms and targeted immunomodulators is redirecting R&D toward precise mechanisms of action, particularly for inflammatory bowel disease where anti-integrin agents and interleukin inhibitors have altered treatment algorithms. At the same time, renewed interest in the gut microbiome has catalyzed investment in microbiome therapeutics and nontraditional interventions, which promise new modalities beyond classic small molecules and proton pump inhibitors.

Concurrently, regulatory authorities are emphasizing adaptive pathways and real-world evidence, which is shaping study design and post-market commitments. This regulatory shift favors programs that integrate pragmatic endpoints, longitudinal patient monitoring, and health economics analyses early in development. Moreover, the distribution and delivery models are evolving; telehealth and remote patient monitoring are increasing the feasibility of home healthcare administration for selected therapies, while hospital-based specialty pharmacies continue to play a pivotal role for complex biologics.

Finally, commercial dynamics are shifting as payers insist on demonstrable value and cost-effectiveness. Manufacturers are responding with innovative pricing and evidence-generation strategies, including outcomes-based contracting and risk-sharing arrangements. Taken together, these shifts demand integrated strategies that span clinical development, regulatory engagement, supply chain planning, and payer dialogue in order to translate scientific advances into sustainable patient access and commercial success.

A strategic assessment of how recent tariff shifts reshape supply chains, manufacturing decisions, and commercial negotiations for gastrointestinal therapeutics

The introduction of new tariff measures in the United States in 2025 has implications that ripple across global supply chains, procurement strategies, and cost structures for gastrointestinal therapeutics. Tariff adjustments influence the cost of active pharmaceutical ingredients, particularly those sourced from international suppliers, and can increase the price pressure on manufacturers who rely on cross-border manufacturing and bulk raw material imports. Consequently, firms must reassess sourcing strategies and contract terms to preserve margins while maintaining product quality and continuity of supply.

In addition to direct cost implications, tariffs can accelerate strategic shifts in manufacturing geography and vertical integration. Companies may respond by nearshoring production of key intermediates, expanding domestic contract manufacturing capacity, or negotiating longer-term supplier agreements to dampen price volatility. These operational responses often require capital expenditure and longer lead times, and they can also affect timelines for clinical supply and commercial rollouts. Moreover, tariff-related cost increases may influence pricing negotiations with payers and hospital systems, prompting manufacturers to invest proactively in value demonstrations and real-world evidence to justify pricing decisions.

Policy uncertainty stemming from tariff regimes also impacts investor sentiment and M&A activity. Some investors may demand clearer visibility on supply chain risk mitigation before committing to sizeable transactions, while others may view tariffs as a catalyst for consolidation and strategic partnerships that secure localized manufacturing. Ultimately, companies that adopt a multifaceted response-combining supplier diversification, contractual protections, and transparent engagement with payers and purchasers-will be better positioned to manage the cumulative impacts while protecting patient access to essential gastrointestinal therapies.

Detailed segmentation analysis highlighting clinical, formulation, and channel differentiators that determine adoption pathways and commercialization priorities across therapeutic categories

Segment-level insights reveal nuanced opportunities and constraints across indications, drug classes, routes of administration, distribution channels, dosage forms, and end users. In indications, acid-related disorders encompass dyspepsia, gastroesophageal reflux disease, and peptic ulcer disease each with distinctive diagnostic and treatment patterns, while infectious gastroenteritis spans bacterial gastroenteritis, parasitic infections, and viral gastroenteritis that differ in acute management and antimicrobial stewardship implications. Inflammatory bowel disease bifurcates into Crohn's disease and ulcerative colitis with divergent surgical and biologic treatment pathways, and irritable bowel syndrome divides into constipation-predominant, diarrhea-predominant, and mixed type presentations that require personalized symptom-targeted approaches.

From a drug class perspective, traditional categories such as aminosalicylates, antibiotics, antidiarrheals, antispasmodics, H2 receptor antagonists, laxatives, and proton pump inhibitors continue to serve core therapeutic needs, while biologics and their subtypes-including anti-integrin agents, anti-tumor necrosis factor agents, and interleukin inhibitors-drive differentiated value in moderate-to-severe inflammatory conditions. Among antibiotics, agents like ciprofloxacin, metronidazole, and rifaximin play specific roles in treating distinct infectious etiologies, which underscores the importance of stewardship and resistance monitoring. Routes of administration, whether oral, parenteral, or topical, influence patient adherence, care setting requirements, and formulation innovation priorities.

Distribution channels such as hospital pharmacy, online pharmacy, and retail pharmacy each impose different commercial and regulatory dynamics that affect reimbursement, patient access, and adherence. Dosage form considerations-injectable solution, oral powder, oral suspension, and tablet capsule-shape manufacturing complexity, cold chain needs, and opportunities for delivery innovation. Finally, end-user segmentation including clinics, home healthcare, and hospitals frames adoption pathways and training requirements for new therapies. Taken together, these segmentation insights suggest that successful product strategies must be tailored across indication-specific clinical needs, differentiated molecule classes, pragmatic route and dosage considerations, and channel- and end-user-specific commercialization plans.

Comparative regional perspectives that illuminate regulatory, payer, and infrastructure variations shaping access, adoption, and supply strategies across global markets

Regional dynamics are pivotal in shaping development priorities and market access strategies, reflecting differences in regulatory frameworks, healthcare delivery systems, and patient demographics. In the Americas, strong clinical research infrastructure, established payer systems, and advanced specialty care networks support the uptake of innovative biologics and complex therapeutic regimens, while also presenting stringent evidence requirements and pricing pressures. As a result, manufacturers must prioritize robust clinical endpoints and health economics evidence to secure formulary placement and reimbursement in these markets.

In Europe, Middle East & Africa, regulatory diversity and varied reimbursement environments create both opportunities and challenges. Western European markets tend to demand comprehensive comparative effectiveness data and value-based narratives, while emerging markets in the region may prioritize affordability and supply chain reliability. Meanwhile, the Middle East and Africa present growth potential tied to expanding healthcare infrastructure and rising chronic disease burden, yet they require tailored access strategies and sensitivity to local procurement processes. Coordinated regional approaches that balance centralized evidence generation with localized commercialization tactics are therefore essential.

Across Asia-Pacific, rapid growth in healthcare investment, an expanding biologics manufacturing base, and evolving regulatory frameworks are key themes. Several markets in the region are enhancing local clinical trial capabilities and accelerating approvals for novel therapies, which can shorten time-to-market when regulatory strategies are well aligned. Nevertheless, price sensitivity and diverse reimbursement mechanisms necessitate flexible pricing and partnership models. In sum, regional strategies must account for distinct regulatory expectations, payer behaviors, and healthcare delivery infrastructures to convert scientific advances into accessible patient care.

A synthesis of corporate strategies and ecosystem partnerships that reveal how innovation, manufacturing, and digital integration are reshaping competitive advantage in the sector

Company-level dynamics in gastrointestinal therapeutics reflect a spectrum of strategic postures from innovation-focused biotechs to large-scale manufacturers and specialized contract service providers. Innovator organizations concentrate on advancing next-generation biologics, targeted small molecules, and microbiome-based interventions, often leveraging precision medicine approaches and biomarker-driven trials to delineate responder populations. These companies frequently pursue strategic partnerships with clinical research networks and academic centers to accelerate proof-of-concept studies and to validate differentiated clinical endpoints.

Meanwhile, established pharmaceutical manufacturers and generic producers are optimizing portfolios through life-cycle management, biosimilar development, and formulation enhancements that improve patient convenience and adherence. Contract manufacturing organizations and specialty CDMOs are expanding capacity to support both injectable biologics and complex oral formulations, which affects speed-to-market and cost structures for sponsors. Across the ecosystem, strategic alliances, licensing deals, and targeted acquisitions remain common mechanisms to complement internal capabilities and to fill pipeline gaps.

Finally, emerging companies and digital health entrants are integrating remote monitoring, patient-reported outcomes, and adherence technologies into product offerings, thereby enhancing real-world evidence collection and value demonstration. Collaboration between therapeutic developers and digital partners is strengthening post-market surveillance and payer negotiations. In aggregate, companies that blend scientific differentiation with operational excellence, payer-aligned evidence strategies, and agile commercialization models will be better positioned to succeed within this competitive landscape.

Operationally focused recommendations that integrate supply chain resilience, evidence alignment, and delivery innovation to strengthen clinical and commercial outcomes in gastrointestinal therapeutics

Industry leaders should adopt a set of pragmatic actions to convert scientific progress into durable commercial outcomes and improved patient care. First, prioritize supply chain resilience by diversifying suppliers of critical active pharmaceutical ingredients and negotiating flexible contracts to mitigate tariff-related and geopolitical risks. Investing in dual-source strategies and strengthening relationships with contract manufacturers will decrease vulnerability and preserve continuity of clinical and commercial supply.

Second, align clinical development with payer expectations through early engagement on endpoints, health economics, and real-world evidence generation. Implement adaptive trial designs and pragmatic studies that reflect clinical practice patterns; this will facilitate value conversations and support formulary negotiations. Third, accelerate delivery innovation by optimizing dosage forms and routes of administration that improve adherence and enable home-based care, while also exploring companion diagnostic strategies to target therapies to likely responders.

Fourth, pursue strategic collaborations that combine strengths across biologics development, microbiome science, and digital health to build differentiated evidence packages and patient support solutions. Fifth, adopt flexible commercialization models that tailor distribution strategies to local channel dynamics, balancing hospital pharmacy partnerships with retail and online pharmacy access where appropriate. Finally, enhance organizational capabilities in regulatory strategy, market access, and commercial analytics to ensure swift adaptation to policy shifts and evolving payer demands. Collectively, these steps will strengthen market positioning and improve patient outcomes.

A transparent, multi-source research methodology combining literature synthesis, expert engagement, and scenario analysis to validate strategic insights and recommendations

The research methodology underlying this analysis integrated multiple evidence streams and iterative validation steps to ensure robustness and relevance. Initially, comprehensive secondary research synthesized peer-reviewed clinical literature, regulatory guidance, patent filings, and treatment guidelines to establish a factual baseline for therapeutic mechanisms, clinical endpoints, and standard-of-care practices. This foundational work identified key knowledge gaps and informed subsequent primary research priorities.

Primary research included structured interviews with clinical experts, payer representatives, manufacturing specialists, and commercial leaders to capture contemporary practice patterns, pricing and reimbursement perspectives, and operational constraints. Insights from these interviews were triangulated with regulatory filings and published clinical trial results to validate assertions and to reconcile divergent viewpoints. In addition, scenario analyses were applied to assess supply chain contingencies and policy impacts, enabling exploration of plausible responses to tariff changes and manufacturing disruptions.

Quality assurance measures involved cross-validation of sources, peer review by subject-matter experts, and transparent documentation of assumptions and limitations. Ethical considerations included confidentiality protections for interview participants and adherence to data privacy standards. While every effort was made to ensure comprehensive coverage, users should interpret insights in the context of evolving clinical evidence and policy developments. The methodology thus combines rigorous literature synthesis, stakeholder engagement, and analytic modeling to produce actionable intelligence for decision-makers.

A concise conclusion that synthesizes strategic imperatives and reinforces the need for integrated, regionally aware approaches to convert innovation into patient impact

In conclusion, the gastrointestinal therapeutics landscape is being reshaped by converging forces: scientific innovation in biologics and microbiome research, regulatory emphasis on real-world evidence, evolving payer expectations for value, and operational pressures stemming from supply chain and policy changes. Navigating these shifts requires integrated strategies that span early clinical design, manufacturing planning, and market access negotiations. Organizations that proactively align evidence generation with payer needs, diversify supply chains, and invest in delivery innovation will secure competitive advantage while enhancing patient outcomes.

Moreover, regional nuances in regulatory and reimbursement environments mean that a one-size-fits-all approach is insufficient. Tailored regional strategies, agile manufacturing footprints, and collaborative partnerships will be critical to achieving both clinical impact and commercial sustainability. The cumulative effect of these actions is to create a more resilient and patient-centered therapeutic ecosystem that can respond to policy shifts and evolving clinical practice.

Stakeholders are therefore encouraged to convert these strategic imperatives into concrete initiatives-prioritizing projects that demonstrate clinical differentiation, operational robustness, and clear value to payers and providers. Doing so will accelerate the translation of scientific breakthroughs into accessible, effective therapies for patients living with gastrointestinal diseases.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of microbiome therapeutic interventions in irritable bowel syndrome management
  • 5.2. Growth of biologics and biosimilars pipeline targeting inflammatory bowel disease mucosal healing strategies
  • 5.3. Expansion of oral small molecule kinase inhibitors for treatment of Crohn's disease and ulcerative colitis
  • 5.4. Advancements in noninvasive diagnostic biomarkers for early detection of gastrointestinal cancers
  • 5.5. Rising demand for personalized medicine approaches leveraging genetic profiling in colorectal cancer therapy selection
  • 5.6. Emergence of home-based telehealth monitoring and digital adherence tools for chronic gastrointestinal disorders
  • 5.7. Increased strategic partnerships between pharma and biotech for microbiome-based therapy commercialization
  • 5.8. Growing investment in next-generation peptide therapies addressing functional dyspepsia and gastroparesis symptoms

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gastrointestinal Diseases Therapeutics Market, by Indication

  • 8.1. Acid-Related Disorders
    • 8.1.1. Dyspepsia
    • 8.1.2. Gastroesophageal Reflux Disease
    • 8.1.3. Peptic Ulcer Disease
  • 8.2. Infectious Gastroenteritis
    • 8.2.1. Bacterial Gastroenteritis
    • 8.2.2. Parasitic Infections
    • 8.2.3. Viral Gastroenteritis
  • 8.3. Inflammatory Bowel Disease
    • 8.3.1. Crohn's Disease
    • 8.3.2. Ulcerative Colitis
  • 8.4. Irritable Bowel Syndrome
    • 8.4.1. Constipation-Predominant
    • 8.4.2. Diarrhea-Predominant
    • 8.4.3. Mixed Type

9. Gastrointestinal Diseases Therapeutics Market, by Drug Class

  • 9.1. Aminosalicylates
  • 9.2. Antibiotics
    • 9.2.1. Ciprofloxacin
    • 9.2.2. Metronidazole
    • 9.2.3. Rifaximin
  • 9.3. Antidiarrheals
  • 9.4. Antispasmodics
  • 9.5. Biologics
    • 9.5.1. Anti Integrin Agents
    • 9.5.2. Anti Tumor Necrosis Factor Agents
    • 9.5.3. Interleukin Inhibitors
  • 9.6. H2 Receptor Antagonists
  • 9.7. Laxatives
  • 9.8. Proton Pump Inhibitors

10. Gastrointestinal Diseases Therapeutics Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral
  • 10.3. Topical

11. Gastrointestinal Diseases Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Gastrointestinal Diseases Therapeutics Market, by Dosage Form

  • 12.1. Injectable Solution
  • 12.2. Oral Powder
  • 12.3. Oral Suspension
  • 12.4. Tablet Capsule

13. Gastrointestinal Diseases Therapeutics Market, by End User

  • 13.1. Clinic
  • 13.2. Home Healthcare
  • 13.3. Hospital

14. Gastrointestinal Diseases Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Gastrointestinal Diseases Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Gastrointestinal Diseases Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. AbbVie Inc.
    • 17.3.2. Johnson & Johnson
    • 17.3.3. Takeda Pharmaceutical Company Limited
    • 17.3.4. Pfizer Inc.
    • 17.3.5. Novartis AG
    • 17.3.6. Ferring B.V.
    • 17.3.7. Gilead Sciences, Inc.
    • 17.3.8. Bausch Health Companies Inc.
    • 17.3.9. AstraZeneca PLC
    • 17.3.10. UCB SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DYSPEPSIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DYSPEPSIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DYSPEPSIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DYSPEPSIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DYSPEPSIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DYSPEPSIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BACTERIAL GASTROENTERITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BACTERIAL GASTROENTERITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BACTERIAL GASTROENTERITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BACTERIAL GASTROENTERITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BACTERIAL GASTROENTERITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BACTERIAL GASTROENTERITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY VIRAL GASTROENTERITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY VIRAL GASTROENTERITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY VIRAL GASTROENTERITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY VIRAL GASTROENTERITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY VIRAL GASTROENTERITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY VIRAL GASTROENTERITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CONSTIPATION-PREDOMINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CONSTIPATION-PREDOMINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CONSTIPATION-PREDOMINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CONSTIPATION-PREDOMINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CONSTIPATION-PREDOMINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CONSTIPATION-PREDOMINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DIARRHEA-PREDOMINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DIARRHEA-PREDOMINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DIARRHEA-PREDOMINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DIARRHEA-PREDOMINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DIARRHEA-PREDOMINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DIARRHEA-PREDOMINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY MIXED TYPE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY MIXED TYPE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY MIXED TYPE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY MIXED TYPE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY MIXED TYPE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY MIXED TYPE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CIPROFLOXACIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CIPROFLOXACIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CIPROFLOXACIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CIPROFLOXACIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CIPROFLOXACIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CIPROFLOXACIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY METRONIDAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY METRONIDAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY METRONIDAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY METRONIDAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY METRONIDAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY METRONIDAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RIFAXIMIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RIFAXIMIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RIFAXIMIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RIFAXIMIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RIFAXIMIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RIFAXIMIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIDIARRHEALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIDIARRHEALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIDIARRHEALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIDIARRHEALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIDIARRHEALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIDIARRHEALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTISPASMODICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTISPASMODICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTISPASMODICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTISPASMODICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTISPASMODICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTISPASMODICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI INTEGRIN AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI INTEGRIN AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI INTEGRIN AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI INTEGRIN AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI INTEGRIN AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI INTEGRIN AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI TUMOR NECROSIS FACTOR AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI TUMOR NECROSIS FACTOR AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI TUMOR NECROSIS FACTOR AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI TUMOR NECROSIS FACTOR AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI TUMOR NECROSIS FACTOR AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI TUMOR NECROSIS FACTOR AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY LAXATIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY LAXATIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY LAXATIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY LAXATIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY LAXATIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INJECTABLE SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INJECTABLE SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INJECTABLE SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INJECTABLE SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INJECTABLE SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INJECTABLE SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL POWDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL POWDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL POWDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL POWDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL POWDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL POWDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL SUSPENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL SUSPENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL SUSPENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL SUSPENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TABLET CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TABLET CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TABLET CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TABLET CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TABLET CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TABLET CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL GASTROINTESTINAL